11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. - Wikidata - awgldk - TriplyDB

11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study.

11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study.

http://www.wikidata.org/entity/Q37699953

about

Exercise-induced cognitive plasticity, implications for mild cognitive impairment and Alzheimer's disease 11 C-PIB-PET for the early diagnosis of Alzheimer’s disease dementia and other dementias in people with mild cognitive impairment (MCI)Passive immunisation with monoclonal anti-Abeta antibodies for the treatment of Alzheimer's disease Alzheimer disease: new concepts on its neurobiology and the clinical role imaging will play Autoantibodies in Alzheimer's disease: potential biomarkers, pathogenic roles, and therapeutic implications Revolutionizing Alzheimer's disease and clinical trials through biomarkers Immunotherapy targeting pyroglutamate-3 Aβ: prospects and challenges Fluid Biomarkers in Clinical Trials of Alzheimer's Disease Therapeutics Targeting the proper amyloid-beta neuronal toxins: a path forward for Alzheimer's disease immunotherapeutics Immunotherapy for Alzheimer's disease: hoops and hurdles Alzheimer's disease: new data highlight nonneuronal cell types and the necessity for presymptomatic prevention strategies Common defects of mitochondria and iron in neurodegeneration and diabetes (MIND): a paradigm worth exploring Testing the right target and right drug at the right stage Developing therapeutic approaches to tau, selected kinases, and related neuronal protein targets Brain imaging in Alzheimer disease Clinical trial methodologies for disease-modifying therapeutic approaches 'Clinical trials in Alzheimer's disease': immunotherapy approaches Amyloid PET in clinical practice: Its place in the multidimensional space of Alzheimer's disease Brain PET in the diagnosis of Alzheimer's disease Development of positron emission tomography β-amyloid plaque imaging agents Developing Medications Targeting Glutamatergic Dysfunction in Autism: Progress to Date 18F-florbetaben Aβ imaging in mild cognitive impairment Crystallization and preliminary X-ray diffraction analysis of the Fab portion of the Alzheimer's disease immunotherapy candidate bapineuzumab complexed with amyloid-β Crystal structure reveals conservation of amyloid-β conformation recognized by 3D6 following humanization to bapineuzumab Immunotherapeutic approaches for Alzheimer's disease High affinity radiopharmaceuticals based upon lansoprazole for PET imaging of aggregated tau in Alzheimer's disease and progressive supranuclear palsy: synthesis, preclinical evaluation, and lead selection Contributions of academic laboratories to the discovery and development of chemical biology tools Bapineuzumab alters aβ composition: implications for the amyloid cascade hypothesis and anti-amyloid immunotherapy Genetic variants in Alzheimer disease - molecular and brain network approaches Amyloid-β peptide-specific DARPins as a novel class of potential therapeutics for Alzheimer disease Toward the treatment and prevention of Alzheimer's disease: rational strategies and recent progress Robust amyloid clearance in a mouse model of Alzheimer's disease provides novel insights into the mechanism of amyloid-beta immunotherapy Modeling of PET data in CNS drug discovery and development.Biomarkers in amyloid-β immunotherapy trials in Alzheimer's disease.Imaging endpoints for clinical trials in Alzheimer's disease.Drug development status for Alzheimer's disease: present scenario.Mild to moderate Alzheimer dementia with insufficient neuropathological changes.Anti-PrPC monoclonal antibody infusion as a novel treatment for cognitive deficits in an Alzheimer's disease model mouse Immunomodulation targeting abnormal protein conformation reduces pathology in a mouse model of Alzheimer's disease.Perspective: prevention is better than cure.

P2860

Q21129438-8F86C1CE-7052-493C-80F1-C4DDBA9B8899 Q24194742-CEE6F75E-FD9F-4388-99B3-420A7FC29FFC Q24197852-230E2A7C-3F99-4928-98E0-50E6E19DB352 Q24594531-12E68373-F0B0-485D-A3E1-A74680326975 Q26740418-E3827165-C9E2-4E5B-8F26-7719763F9F68 Q26744882-31F9172A-870A-4154-89E0-80EA278D9CBB Q26745928-CE2940EC-A832-4AC1-9C64-5E93E19F8279 Q26784569-2A814A82-205D-4DDD-AD0A-5325177F8267 Q26822002-54ACEFCD-CFB2-4520-89CF-F48C7622E9A6 Q26823877-66933AF2-DE98-4D9A-A76B-74FBB743E3D6 Q26852851-6350B153-DE98-4F04-8FF5-F3CA3B8F6799 Q26861082-72BFC25E-5D8F-442E-886E-C4F4C7AEB530 Q26864854-8471F3DF-39D3-4B02-AD9F-22E57D5EF23D Q26865654-4BD094E0-E0F6-4BCE-A0BC-AA9604A57B89 Q26996299-913FD6F7-EF40-4A32-8910-75BA3A9E4EF3 Q27001770-CE034415-69DD-4D1E-85D3-636B669FA1CF Q27008979-214B68C2-A1BF-43A2-BE84-DD97E006ED85 Q27009411-836F1284-AA94-4C5A-8891-83775B8F7E33 Q27011549-6937B189-AAC9-43CD-9F89-66703D46BA8D Q27012742-ACDE818F-801D-4548-BDC3-BC6AB805CC5C Q27025683-AEEAD205-E06B-4910-AA6D-C5A8E750CFB1 Q27499311-68B0D383-198C-44A1-AEF5-7167D30C07F7 Q27682022-292A3868-736E-4686-BF82-2B645D866885 Q27684692-BC993A3E-DF0E-4961-AC98-3E59A5DB6BC9 Q28081278-F40AAB66-BE98-46BD-96AF-8EB0341F9420 Q28241366-9994B34F-27DF-4EE3-8E44-CA51AD57D2AB Q28389188-B0F89482-A438-45C8-AEB5-27E01A6318C6 Q28488690-0D81F486-1257-4545-863A-08BD86A66884 Q28596011-502010F0-15FF-431B-BEBF-8120C3A32568 Q28655482-D56899D8-B44A-4C81-BEB4-9F190F547182 Q30419992-93C13CF3-D4FD-4D6F-AB14-9C2C4A780403 Q30499456-B3A37EDE-DF19-4C95-A69C-9ABCC317BEB9 Q30623699-4D11A072-0F7A-440A-BBC1-7CA5FECD40C7 Q30651551-9EE95A13-34FB-46CD-93D7-FE885715EA12 Q30885979-59CAB84C-CC9B-49FE-B10E-24E072BFE851 Q33355252-EA644D26-2565-42FB-9ACB-68DF20E9C8D9 Q33592693-3F322B65-4202-4ACB-96F6-5B447197B929 Q33718694-1A36B6C1-416E-44EF-AAC7-65C95E513D53 Q33725397-40C49FF8-609F-4281-A5BA-7845A587031D Q33737438-151C5695-6C7C-4595-88DE-13DCDD9D599E

P2860

11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study.

http://www.wikidata.org/entity/Q37699953

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 26 February 2010

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

11C-PiB PET assessment of chan ...... trolled, ascending-dose study.

@en

11C-PiB PET assessment of chan ...... trolled, ascending-dose study.

@nl

type

label

11C-PiB PET assessment of chan ...... trolled, ascending-dose study.

@en

11C-PiB PET assessment of chan ...... trolled, ascending-dose study.

@nl

prefLabel

11C-PiB PET assessment of chan ...... trolled, ascending-dose study.

@en

11C-PiB PET assessment of chan ...... trolled, ascending-dose study.

@nl

P1433

Q37699953-AB473BC5-3CC1-46D6-A335-6E0D5DA105AE

P1476

Q37699953-FD031B5A-A36E-4A15-9CE9-57B8E30C2F1A

P2093

Q37699953-1549148E-2FF6-48A0-9149-59D44FC1F7FA

Q37699953-47BCB7C2-E508-45CF-8844-AF0BAA54BF95

Q37699953-4CF8C1B6-6A70-426D-BFA3-EE869258E810

Q37699953-72D989F0-4033-4F5D-910B-E3C35254E46A

Q37699953-795F450E-589E-48A2-8CB9-994E60FED19B

Q37699953-79671779-6F3D-44C4-A9C8-1380FED75610

Q37699953-7BF745AA-9EBD-40E5-AA04-6898220F3272

Q37699953-8AC68E5B-EF19-462B-BBA9-B1CA8B4B5E8A

Q37699953-8BC2A0CC-44D0-48FE-8A18-E62D704B65EC

Q37699953-9F68A1F9-CB77-4F4C-B312-4E872EBB6DC7

P304

Q37699953-88E0A3FA-2AA0-4036-A232-4F4F9D21E9AB

P31

Q37699953-0765F7B8-69AC-4C89-928E-7CB21F095D3D

P356

Q37699953-83206CD5-BF47-4BD2-8C63-942BA747656F

P433

Q37699953-AE62FDDF-4ADB-4B38-97C6-9C3B3AF79DDB

P478

Q37699953-B99776C8-88CD-4CE0-9F34-5CE43C735122

P50

Q37699953-3B6454C7-6F42-424E-A6F8-66F2BE0338EE

Q37699953-4A7B8F36-A3E2-4A6F-82EB-2BD65D8F5B94

Q37699953-4D39E5CE-7469-4B41-A5B0-640988B15F01

Q37699953-D37456DF-E03A-4832-8B57-A361D509060D

Q37699953-E63B8059-6B19-4644-95E4-BACD341853D7

P577

Q37699953-26050FCE-6E10-4FD2-A25D-40F0ECFB1F4D

P698

Q37699953-864000FD-2FB9-40F2-AC2C-255645B4FDD4

P921

Q37699953-00B7AB25-E643-49EC-A417-7E75C930B626

Q37699953-730095B9-3952-4733-981A-13677741AD06

P356

S1474-4422(10)70043-0

P1433

Lancet Neurology

P1476

11C-PiB PET assessment of chan ...... trolled, ascending-dose study.

@en

P2093

Aren A Okello

http://www.w3.org/2001/XMLSchema#string

Chester A Mathis

http://www.w3.org/2001/XMLSchema#string

Dale Schenk

http://www.w3.org/2001/XMLSchema#string

Enchi Liu

http://www.w3.org/2001/XMLSchema#string

Jerome Barakos

http://www.w3.org/2001/XMLSchema#string

Juha O Rinne

http://www.w3.org/2001/XMLSchema#string

Keith M Gregg

http://www.w3.org/2001/XMLSchema#string

Martin Koller

http://www.w3.org/2001/XMLSchema#string

Michael Grundman

http://www.w3.org/2001/XMLSchema#string

Roger Bullock

http://www.w3.org/2001/XMLSchema#string

P304

363-372

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/S1474-4422(10)70043-0

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

9

http://www.w3.org/2001/XMLSchema#string

P50

William E. Klunk

David J. Brooks

P577

2010-02-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20189881

http://www.w3.org/2001/XMLSchema#string

P921

Alzheimer's disease